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Abstract
Background:  Gelsolin-like actin-capping protein (CapG) is a ubiquitous gelsolin-family actin-modulating protein
involved in cell signalling, receptor-mediated membrane ruffling, phagocytosis, and motility. CapG has generated great
interest due to its oncogenic function in the control of cell migration or invasion in a variety of cancer cells. We
previously applied proteomic methods to characterize differentially expressed proteins in oral squamous-cell carcinoma
(OSCC) cells and detected significantly high expression levels of CapG in OSCC-derived cell lines compared to human
normal oral keratinocytes. In the current study, to further determine the potential involvement of CapG in OSCC, we
evaluated the status of CapG protein and mRNA expression in human oral premalignant lesions (OPLs) and primary
OSCCs and correlated the results with clinicopathologic variables.
Methods: Matched normal and tumour tissue sections of 79 human primary OSCCs and 28 OPLs were analyzed for
CapG expression by immunohistochemistry (IHC). Correlations between CapG-immunohistochemical staining scores
of OSCCs and clinicopathologic features were evaluated by Fisher's exact test. Real-time quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) was used to estimate CapG expression at the mRNA level.
Results: In IHC, substantial up-regulation of CapG protein was observed in primary OSCCs (52%) and OPLs (64%),
whereas corresponding normal tissues showed consistently weak or absent immunoreactivity of CapG. qRT-PCR data
were consistent with the protein expression status. Moreover, CapG expression was correlated with the TNM stage
grading of OSCCs.
Conclusion: Our finding of frequent dysregulated expression of CapG in premalignant and malignant lesions together
with an association with an advanced clinical disease stage suggests that CapG could contribute to cancer development
and progression and that CapG may have potential as a biomarker and a therapeutic target for OSCC.
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Background
Oral squamous cell carcinoma (OSCC) is a major cause of
morbidity and mortality globally, accounting for 275,000
new cases and more than 120,000 deaths annually [1-3].
Despite therapeutic and diagnostic advances, patients
often are diagnosed at advanced stages and mortality rates
are still increasing [4]. This highlights the need for contin-
ued efforts to discover suitable biomarkers for early dis-
ease diagnosis and to understand the disease pathogenesis
as a first step toward improving treatment. Considering
these problems, it is imperative to study oral carcinomas
at the genetic level and to characterize the genetic changes
responsible for carcinogenesis and tumour behaviour.
Because proteomics-based profiling uniquely allows
delineation of global changes in expression patterns
resulting from transcriptional and posttranscriptional
control and posttranslational modifications, proteomic
tolls are used increasingly in the post-genomic era to dis-
cover new cancer biomarkers [5,6]. We recently developed
a strategy of using proteomics technologies to search for
significant molecular biomarkers characteristic of oral car-
cinogenesis [7-10]. Among the proteins identified, CapG
expression was found to be up-regulated in OSCC-derived
cell lines compared to human normal oral keratinocytes
using a fluorescent two-dimensional differential in-gel
electrophoresis (2-D-DIGE) system and matrix-assisted
laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF/MS).
CapG, also known as macrophage capping protein, is a
348-amino acid protein that is ubiquitously expressed in
normal tissues and particularly abundant in macrophages
[11-13]. CapG is a member of the actin-binding protein,
which is crucial for the organization of the actin cytoskel-
eton. The actin cytoskeleton underlies many cellular func-
tions including the maintenance and mutability of cell
shape, motility, adherence, and growth regulation [14-
16]. Since these cellular functions have escaped normal
control mechanisms during carcinogenesis, the behaviour
of actin and actin-binding proteins has undergone intense
scrutiny as a potential contributor to malignant transfor-
mation and a target for anticancer drug development [17-
19]. Evidence indicates that CapG also possesses an onco-
genic function involved in the control of cell migration or
invasion, and we hypothesized that the protein has poten-
tial as an emerging therapeutic target of interest for the
treatment of oral cancer. However, it is unclear whether
CapG is associated with oral carcinogenesis. The purpose
of the current study was to determine CapG protein/
mRNA expression in a series of human primary OSCCs
and human oral premalignant lesions(OPLs) and corre-
late the protein expression with the clinical relevance in
patients with OSCC.
Methods
Tissue specimens
Seventy-nine pairs of primary OSCC samples and corre-
sponding normal oral epithelium tissues or 28 OPLs
(diagnosed as oral leukoplakias) were obtained at the
time of surgery performed at Chiba University Hospital
between 1998 and 2006. All patients provided informed
consent according to the protocol that was reviewed and
approved by the institutional review board of Chiba Uni-
versity before any procedures were performed. The
resected tissues were divided into two parts: one was fro-
zen immediately after removal of the surrounding normal
tissue and stored at -80°C until RNA extraction, and
another was fixed in 10% buffered formaldehyde solution
for pathologic diagnosis and immunohistochemical
staining. Histopathologic diagnosis of each tumour spec-
imen was carried out according to the International Histo-
logical Classification of Tumors by the Department of
Pathology, Chiba University Hospital. Clinicopathologic
staging was determined by the TNM classification of the
International Union against Cancer. All OSCC samples
were histologically confirmed and checked to ensure the
presence of tumour in greater than 80% of specimens.
Cell culture
The OSCC-derived cell lines used in this study were HSC-
2, HSC-3, and Ca9-22 (Human Science Research
Resources Bank, Osaka, Japan). All OSCC-derived cell
lines were cultured in Dulbecco's modified Eagle medium
F-12 HAM (Sigma-Aldrich Co.), supplied with 10% heat-
inactivated fetal bovine serum (Sigma) and 50 U/ml-1
penicillin and streptomycin (Sigma), and incubated at
37°C in a humidified atmosphere with 5% CO2.
Protein and mRNA extraction
Protein was extracted when the cells reached 80% to 90%
confluence; they were washed twice with phosphate buff-
ered saline (PBS), scraped into a tube, and centrifuged
briefly. The cell pellets were incubated for 30 min in a lysis
buffer containing 7 M urea, 2 M thiourea, 4% w/v CHAPS,
and 10 mM Tris pH 8.0, and lysed by sonication (3 × 10
sec pulses on ice). The sample was centrifuged at 13,000
rpm for 20 min. The supernatant containing the cell pro-
teins then was recovered and the protein concentration
was measured with a Protein Assay Kit (Bio-Rad Laborato-
ries) and adjusted to 1 mg/ml with lysis buffer. The pH of
the protein sample was adjusted to 8.5 with 30 mM Tris-
HCl. Total RNA was extracted using Trizol Reagent (Invit-
rogen Life Technologies) according to the manufacturer's
instructions. Each extracted RNA or protein was stored
separately at -80°C until use.
Immunohistochemistry
To examine the cellular distribution of CapG protein in
oral lesions, we carried out immunohistochemical stain-BMC Cancer 2008, 8:39 http://www.biomedcentral.com/1471-2407/8/39
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ing on 4-μm sections of paraffin-embedded specimens.
Briefly, after deparaffinization and hydration, the slides
were pretreated in 10 mM sodium citrate buffer (pH 6.0)
in a microwave oven for 5 min at 95°C. The endogenous
peroxidase activity was quenched by 30-min incubation
in a mixture of 0.3% hydrogen peroxide solution in 100%
methanol. After being washed with PBS buffer, the sec-
tions then were incubated with primary antibody affinity-
purified goat antihuman CAPG polyclonal antibody
(1:500 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA; catalogue number: sc-33084) at room temperature in
a moist chamber overnight. After being washed with PBS
buffer, the slides were treated with biotinylated secondary
antibody for 1 hr followed by colour development in 3, 3'-
diaminobenzidine tetrahydrochloride (DAKO JAPAN
Inc., Kyoto, Japan). Finally, the slides were lightly counter-
stained with hematoxylin. A negative control was estab-
lished by replacing the primary antibody with PBS. To
quantitate the state of CapG protein expression, the mean
percentage of positive tumour cells was determined in at
least five random fields at 400 × magnification in each sec-
tion. The intensity of the CapG immunoreaction was
scored as follows: 1+, weak; 2+, moderate; and 3+,
intense. Three target cell types, i.e., normal, premalignant,
and malignant epithelial cells, were identified for scoring.
The percentage of CapG-positive cells and the staining
intensity then were multiplied to establish a CapG-immu-
nohistochemical (CapG-IHC) staining score. Cases with a
CapG-IHC score exceeding 78.68 (maximum score of nor-
mal tissues) were considered positive. Two independent
pathologists, neither of whom had knowledge of the
patients' clinical status, made these judgments.
Western blot analysis
To confirm the specificity of the CapG antibody used,
three Western blot examinations were carried out on three
OSCC-derived cell lines (HSC-2, HSC-3, and Ca9-22).
Protein extracts were electrophoresed on 11% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels,
transferred to polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad), and blocked for 1 hr at room tempera-
ture in 5% skim milk. Immunoblot PVDF membranes
were washed five times with 0.1% Tween 20 in TBS (TBS-
T), and 2 μg ml-1 affinity-purified goat antihuman CAPG
polyclonal antibody (1:5000 dilution; Santa Cruz Bio-
technology) was added directly to the TBS-T solution for
2 hr at room temperature. The PVDF membranes were
washed again and incubated with 1:10,000 ratio of anti-
goat IgG (Nichirei Biosciences Inc., Tokyo, Japan; cata-
logue number: 414161) as a secondary antibody for 20
min at room temperature. The membranes then were
incubated with Enhanced ChemiLuminescence (ECL)+ -
HRP HORSERADISH PEROXIDASE? substrate solution
included in the ECL+ kit (Amersham Biosciences), and
immunoblotting was visualized by exposing the mem-
brane to Hyperfilm (Amersham Biosciences).
mRNA expression analysis
The expression levels of CapG mRNA were examined in 50
OSCC specimens from patients with primary tumours
among the OSCC cases studied by IHC staining. Control
reactions were prepared in parallel without reverse tran-
scriptase (RT). Before cDNA synthesis, residual genomic
DNA was removed from the total RNA using DNase I
treatment (DNA-free; Ambion, Austin, TX). The primer
sequences used to analyze CapG mRNA expression were 5-
CTCACAGCTGACAAGGCAAA-3 (nucleotides 965–984)
and 5-CCACCCTCATTTCCAGTCC-3 (nucleotides
1303–1321). The sequences of specific primers were
checked before use to avoid amplification of genomic
DNA or pseudogenes by the Primer3 program [20].
Amplified products were analyzed by 3% agarose gel elec-
trophoresis to ascertain size and purity. Real-time quanti-
tative RT-polymerase chain reaction (qRT-PCR) was
performed with a single method using the LightCycler
FastStart DNA Master SYBR Green I kit (Roche, Man-
nheim, Germany). To prepare the standard curve, 3 μg of
total RNA from normal oral tissue was reverse-transcribed
with Superscript RT (Life Technologies, Grand Island, NY)
and oligo-d(T)12–18 primer, after which serial dilutions
were made corresponding to cDNA transcribed from 300,
30, 3.0, and 0.3 ng of total RNA. PCRs using LightCycler
apparatus were carried out in a final volume of 20 μl of
reaction mixture consisting of 2 μl of FirstStart DNA Mas-
ter SYBR Green I mix, 3 mM MgCl2, and 0.2 μl of primers,
according to the manufacturer's instructions. The reaction
mixture then was loaded into glass capillary tubes and
submitted to an initial denaturation at 95°C for 10 min,
followed by 45 rounds of amplification at 95°C (10 sec)
for denaturation, 58°C (10 sec) for annealing, and 72°C
for extension, with a temperature slope of 20°C/sec, per-
formed in the LightCycler. The transcript amount for
CapG was estimated from the respective standard curves
and normalized to the GAPDH transcript amount deter-
mined in corresponding samples.
Statistical analysis
Differences in gene expression levels between CapG-posi-
tive and CapG-negative cases were calculated with the
Mann-Whitney's U-test. Correlations between CapG-IHC
scores and clinicopathologic features were evaluated by
Fisher's exact test. The criterion for statistical significance
was P < 0.05. Mean values are shown with the standard
error.
Results
Immunohistochemical analysis
IHC staining was performed using a series of surgical spec-
imens, including 79 OSCCs with corresponding normalBMC Cancer 2008, 8:39 http://www.biomedcentral.com/1471-2407/8/39
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tissues and 28 OPLs. Representative results for CapG pro-
tein expression in normal oral tissues, OPLs, and primary
OSCCs are shown in Figure 1. Normal oral mucosal spec-
imens had no or faint CapG immunoreactivity in almost
all epithelium cells and were considered CapG-negative.
In contrast, 41 of 79 (52%) cases of OSCCs examined had
significantly increased expression of CapG immunoreac-
tivity in the nucleus and cytoplasm of the tumour cells
(IHC score > 78.68; maximum score of normal tissues). In
OPL specimens, positive CapG immunoreactivity was
detected distinctly on spinous cells in 18 of 28 cases
(64%). Stromal components such as fibroblasts, lym-
phocytes, endothelial cells, and macrophages also exhib-
ited positive CapG immunoreactivity, the last of which
CapG is known to be homogeneously expressed in both
normal and tumour specimens. In the current study, we
focused on CapG expression in epithelium cells. The spe-
cificity of the primary antibody also was evaluated. A sin-
gle band was recognized at the appropriate molecular
weight of CapG protein on Western blot analysis as
reported by Johnston et al [21] (see additional file 1). Fur-
thermore, no IHC staining was observed when OSCC tis-
sue was analyzed without the primary antibody (Figure
1D).
The CapG-IHC scores for normal tissues, OPLs, and
OSCCs ranged from 0 to 79 (mean, 17.14), 6 to 204
(mean, 65.36), and 3 to 287 (mean, 96.19), respectively.
CapG expression levels in primary OSCCs and OPLs were
significantly (P < 0.01) higher than those in normal oral
tissues (Figure 2A). In contrast, there was no significant (P
= 0.80) difference in CapG-IHC scores between OSCCs
and OPLs. The correlation between the clinicopathologic
characteristics of the patients with OSCC and the status of
CapG expression is summarized in Table 1. CapG protein
expression was correlated with OSCC tumor size (P =
0.014). Moreover, the CapG-IHC scores for early stages (I
and II) and advanc ed stages (III and IV) ranged from 3.62
to 160.3 (mean, 60.54) and 4.95 to 287.4 (mean, 107.4),
respectively. The CapG expression levels were significantly
higher in the OSCC group with advanced-stage disease
compared with the group with early-stage disease (Mann-
Whitney U-test, P < 0.001) (Figure 2B).
mRNA expression analysis
qRT-PCR analysis data were matched to protein expres-
sion levels studied by IHC scores. The CapG mRNA
expression levels significantly increased in primary
tumours of randomly selected CapG-positive cases (n =
10) compared with randomly selected CapG-negative
cases (n = 10, Mann-Whitney U-test, P < 0.001) (Figure
2C). The relative mRNA expression levels in negative and
positive cases ranged from 0.16 to 1.15 (mean, 0.75) and
2.72 to 9.22 (mean, 5.67), respectively. Therefore, CapG
mRNA expression levels were consistent with the protein
expression.
Discussion
Tumour-associated processes such as invasion and metas-
tasis are critically dependent on dynamic alterations in the
organization of the actin cytoskeleton. Dysregulation of
actin-based motility is a prominent factor in cell transfor-
mation and probably is associated with carcinogenesis
[22,23]. To date, a large number of actin-binding proteins
have been cloned, many of which are involved in the
malignant transformation process; and distinctive protein
expression patterns of some of these genes in cancer and
progressive carcinogenesis processes have been observed
[24-28]. Previously, we reported significant overexpres-
sion of the actin-binding protein CapG expression at the
protein level in OSCC-derived cell lines using a 2-D-DIGE
system and MALDI-TOF/MS [7].
CapG is a member of the gelsolin superfamily of the actin-
binding proteins [29]. In addition to respective roles in
actin filament remodelling, the proteins of the gelsolin
superfamily have specific roles in several cellular proc-
esses, including cell motility, signal control, and apopto-
sis and regulation of phagocytosis [30,31]. Variations in
expression of the gelsolin superfamily proteins are
thought to affect major cytoskeletal changes during differ-
entiation and carcinogenesis, and considerable evidence
Representative results of immunohistochemical staining of  CapG in normal tissues, OPLs, and primary OSCCs Figure 1
Representative results of immunohistochemical 
staining of CapG in normal tissues, OPLs, and pri-
mary OSCCs. A: Normal oral tissue exhibits negative 
CapG protein expression (original magnification × 100); B: 
CapG-positive case of OPL. The immunoreaction is 
enhanced in the spinous layer (original magnification × 100); 
C: CapG-positive case of OSCC (stage IV). Strong positive 
immunoreactivity for CapG is detected in the nuclear and 
cytoplasm (original magnification × 200); D: The same OSCC 
sample is immunostained in the absence of the primary anti-
body (original magnification × 200).
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has shown a significant association between the proteins
and a wide range of human malignancies including
OSCCs [32-35]. Experimental evidence has shown that
CapG also is crucial for regulating cell motility [36,37];
however, its exact function in the development and pro-
gression of malignant tumours remains controversial.
Watari et al. reported an apparent decrease in CapG pro-
tein levels in some human tumor cell lines compared with
their corresponding benign counterparts. In addition,
those investigators showed that CapG protein expression
reduces the ability of a transformed cell to induce tumour
formation, suggesting that CapG is a tumour suppressor
gene [38]. However, accumulating evidence has indicated
a number of theories on the possible function of CapG as
a tumor activator. A recent study identified CapG as a tar-
get of the AP-1 transcription factor complex, which has
emerged as a critical regulator of gene expression in
response to the activation of a variety of oncogenic signal
transduction cascades, including c-Fos and c-Jun [39]. De
Corte et al. reported that overexpression of CapG pro-
CapG protein and mRNA expression in normal tissues, OPLs, and primary OSCCs Figure 2
CapG protein and mRNA expression in normal tissues, OPLs, and primary OSCCs. A: CapG protein expression in 
OPLs (n = 28) and OSCCs (n = 79) is significantly higher than in normal oral tissues (n = 79; P < 0.01, Mann-Whitney's U-test). 
The results are expressed as the mean ± SD; B: States of CapG protein expression in early-stage (I and II) OSCC (n = 27) and 
advanced stages (III and IV) OSCC (n = 52) are compared. CapG protein expression in advanced stages is significantly higher 
than in the early stages (P < 0.001, Mann-Whitney U-test); C: Comparison of CapG mRNA expression levels between CapG-
positive and CapG-negative cases in primary OSCCs classified by IHC analysis. There is a significant difference in the CapG 
mRNA expression levels between the negative and positive cases (P < 0.001, Mann-Whitney's U-test).
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motes cancer cells to invade collagen through the Ras-
phosphoinositide 3-kinase signaling pathway [40]. More
recently, they reported that targeting human cancer cells,
including breast and prostate cancer cells with an RNAi
procedure against CapG, significantly reduced the inva-
sive and motile properties of both cells examined as well
as cell aggregation [41]. Similar results were obtained by
others in pancreatic cancer cells [42]. These findings sup-
port the hypothesis that CapG also is a tumour activator.
Furthermore, significant overexpression of CapG was
reported at both the mRNA and protein levels in several
types of human primary tumours, i.e., ocular melanomas
[43], glioblastomas [44], and pancreatic ductal adenocar-
cinomas [42], all of which are aggressive cancers that kill
patients by metastasis and local invasion. Because OSCC
is also a solid neoplasm exhibiting aggressive tumour phe-
notypes, we hypothesized that CapG is a potential emerg-
ing therapeutic target of interest for the treatment of oral
cancer. However, the status of CapG in OSCC remains
unclear and therefore we selected it for further investiga-
tion.
To confirm our hypothesis, we determined the protein/
mRNA expression in a series of human primary OSCCs
using IHC. By evaluating the CapG-IHC scores, significant
up-regulation was evident in the primary OSCCs com-
pared with normal tissues (P < 0.01). The CapG protein
expression levels in primary OSCCs were significantly
associated with tumor size (P = 0.014). In pancreatic duc-
tal adenocarcinomas, a clinical study also showed that
high CapG expression was correlated with increased
tumour size [42], which was consistent with results
obtained in the current study. Moreover, the state of CapG
protein expression differed significantly between the early
stages (I and II) and the advanced stages (III and IV)
(Mann-Whitney U-test, P < 0.001). Given the known roles
Table 1: Correlation between the Expression of CapG and Clinical Classification in OSCCs.
Immunostaining Results No. patients (%)
Clinical Classification Total Capg (-) Capg (+) P Valuea
Age at surgery (years)
< 60 30 15 (50) 15 (50)
60 =<, < 70 22 11 (50) 11 (50) 0.920408
70 =< 27 12 (44) 15 (56)
Gender
Male 53 23 (43) 30 (57) 0.337982
Female 26 15 (58) 11 (42)
T-primary tumour
T1 4 4 (100) 0 (0)
T2 25 16 (64) 9 (36) 0.0140021
T3 24 10 (42) 14 (58)
T4 26 8 (31) 18 (69)
N-regional lymph node
N (-) 50 27 (54) 23 (46) 0.242807
N (+) 29 11 (38) 18 (62)
Stage
I4 4  ( 1 0 0 ) 0  ( 0 )
II 15 10 (67) 5 (33) 0.0191771
III 19 10 (53) 9 (47)
IV 41 14 (34) 27 (66)
Histopathologic type
Well differentiated 46 23 (50) 23 (50)
Moderately differentiated 28 12 (43) 16 (57) 0.714701
Poorly differentiated 5 3 (60) 2 (40)
Tumour site
Tongue 34 20 (59) 14 (41)
Gingiva 26 9 (35) 17 (65) 0.110879
Oral floor 8 5 (63) 3 (37)
Buccal mucosa 6 1 (17) 5 (83)
Oropharynx 4 3 (75) 1 (25)
Lip 1 0 (0) 1 (100)
Leukoplakia 28 10 (36) 18 (64)
aP < 0.05 was considered significant.BMC Cancer 2008, 8:39 http://www.biomedcentral.com/1471-2407/8/39
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of CapG in cytoskeletal organization and cell migration,
these findings indicated the potential clinical significance
of CapG as a marker or prospective therapeutic target for
the most aggressive forms of OSCCs. Furthermore, high
levels of CapG protein expression were detected even in
the OPLs examined, suggesting that CapG may play an
important role in early-stage OSCC development. How-
ever, the development of OSCC is generally predicated on
the development of multiple clonal genetic alterations
[45,46], and additional research is needed to establish
whether and how CapG-stained OPLs give rise to strongly
CapG-stained OSCCs.
Conclusion
Significant overexpression of the actin-binding protein
CapG was detected not only in 52% of OSCCs but also in
64% of OPLs. Enhanced expression of CapG was associ-
ated with large tumour size and advanced staging of
OSCCs. Based on our data, we concluded that CapG may
initiate or activate the neoplastic process of OSCC cells
including the regulation of biologic behaviour of aggres-
sive forms of cells rather than as a suppressor. In addition,
CapG may serve as a useful diagnostic biomarker or a
therapeutic target to identify and treat patients with
advanced OSCCs. The current results together with previ-
ously reported evidence suggest that CapG provides an
attractive molecular target for decreasing invasiveness and
the metastatic properties of tumors. Further studies may
provide insights into the process of tumorigenicity and for
planning new treatment strategies.
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